In bone scintigraphy using 99mTc with methylenediphosphonate (99mTc-MDP) and
hydroxymethylenediphosphonate (99mTc-HMDP), it takes 2− 6 h after an injection before …

Nuclear medicine bone imaging has been the optimum diagnosis for the detection of bone
disorders because the lesion could be detectable before the appearance of symptomatic …

To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative …

INTRODUCTION: The preferable pharmacokinetics of rhenium-186 (186Re)-
monoaminemonoamidedithiol-conjugated or 186Re-mercaptoacetyltriglycine-conjugated …

Bone scintigraphy with 99mTechnetium-methylenediphosphonate (99mTc-MDP) or
99mTechnetium-hydroxymethylenediphosphonate (99mTc-HMDP) presents several …

INTRODUCTION: 68Ga is a radionuclide of great interest as a positron emitter for positron
emission tomography (PET). To develop a new bone-imaging agent with radiogallium, 1, 4 …

For the currently used 99mTc-labeled diphosphonates such as 99mTc-MDP and 99mTc-
HDP, the required interval of 2.5 to 3 h between injection and the scintigraphic bone imaging …

A series of novel zoledronic acid (ZL) derivatives 1-hydroxy-3-(2-methyl-1 H-imidazol-1-yl)
propane-1, 1-diyldiphosphonic acid (MIPrDP), 1-hydroxy-4-(2-methyl-1 H-imidazol-1-yl) …

INTRODUCTION: To enable imaging at an earlier time after injection, a radiopharmaceutical
with higher affinity for bone, larger ratio of bone-to-soft tissue uptake and more rapid …

INTRODUCTION: Based on the concept of bifunctional radiopharmaceuticals, we have
previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of …